Key Stats for ACLX Stock
- Price Change for ACLX stock: +77.43%
- ACLX Share Price as of Feb. 23: $113.75
- 52-Week High: $114
- ACLX Stock Price Target: $111
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Arcellx (ACLX) stock jumped over 77% on Monday after Gilead Sciences announced a deal to acquire the company for up to $7.8 billion. Gilead agreed to pay $115 per share in cash plus a $5 contingent value right tied to future anito‑cel sales, so the offer values Arcellx at a significant premium to its prior close.
The offer price delivers about a 79% premium to Arcellx’s closing price before the deal. As a result, the stock quickly trades near that level and hits a record high. This acquisition builds on the companies’ existing collaboration around anitocabtagene autoleucel (anito‑cel). The therapy is a BCMA‑directed CAR T‑cell treatment for relapsed or refractory multiple myeloma that uses Arcellx’s D‑Domain binder technology.
Anito‑cel is in a pivotal Phase 2 trial and a planned global Phase 3 trial. It has also received Fast Track, Orphan Drug, and RMAT designations from the FDA, so regulators support expedited development in a large unmet‑need cancer market.
Gilead projects that the transaction will boost its earnings per share starting in 2028 if anito‑cel gains approval. This outlook underscores how central the therapy is to the deal’s strategic rationale.
Beyond the buyout news, Arcellx has been steadily building clinical momentum in 2026. In January, the company and Kite highlighted new anito‑cel data and access initiatives at the Tandem Meetings of ASTCT and CIBMTR. They emphasized high target specificity and encouraging efficacy in multiple myeloma, and these updates helped set expectations before the deal announcement.
See analysts’ growth forecasts and price targets for ACLX stock (It’s free!) >>>
What the Market Is Telling Us About ACLX Stock
The one‑day 77% surge to around $114 signals that investors now see Arcellx mainly through the lens of the Gilead takeout rather than as a standalone, high‑risk biotech. As a result, the market anchors ACLX’s value near the $115‑per‑share cash offer.
It also prices in only limited additional upside today for the $5 sales‑based CVR. Because the 52‑week high now sits just above the current price, trading action suggests investors view deal completion as the primary near‑term catalyst. Instead, they pay less attention to independent earnings or pipeline milestones.
Even after the rally, Arcellx’s market cap of about $6.6 billion and enterprise value of roughly $6.1 billion line up with Gilead’s announced equity value for the transaction. The stock’s 5‑year beta of 0.36 and a free‑float of about 68%, therefore, suggest relatively low historical volatility and a reasonably distributed shareholder base.
This profile can help arbitrageurs manage risk as they assess closing probabilities. In addition, Arcellx has net cash of roughly $524 million and no meaningful near‑term debt pressure, so Gilead inherits a balance sheet that can support ongoing trials and integration without immediate refinancing needs.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Arcellx, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ACLX, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track ACLX alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Arcellx stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
